Related Experiment Videos
Long-term results with primary retroperitoneal tumors
C W Pinson1, S G ReMine, W S Fletcher
1Department of Surgery, Oregon Health Sciences University, Portland.
Archives of Surgery (Chicago, Ill. : 1960)
|October 1, 1989
Summary
Primary retroperitoneal tumors are diverse, with sarcomas being most common. Resection rates and survival vary significantly by tumor type, with benign tumors offering the best prognosis and undifferentiated tumors/carcinomas the worst.
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Primary retroperitoneal tumors are rare and diverse, posing diagnostic and therapeutic challenges.
- Preoperative diagnosis is often difficult, with only 39% of cases recognized before surgery in this study.
- Tumor type significantly influences treatment strategies and patient outcomes.
Purpose of the Study:
- To analyze the characteristics, treatment, and survival outcomes of primary retroperitoneal tumors.
- To identify factors influencing resectability and patient prognosis.
Main Methods:
- Retrospective review of 182 patients with primary retroperitoneal tumors.
- Analysis of surgical resection rates, operative details, and pathological findings.
- Evaluation of survival data based on tumor type, treatment, and other prognostic factors.
Main Results:
- Sarcomas were the most frequent type (43%), followed by lymphomas (23%).
- Resection rates varied by tumor type, with 69% of sarcomas and nearly 100% of benign tumors resected.
- Survival rates were highest for benign tumors (100% at 5 years) and lowest for undifferentiated tumors and carcinomas (less than 33% at 1 year).
- Operative mortality was 6%, and tumor caused late death in 95% of patients.
Conclusions:
- Tumor type, grade, and extent are critical determinants of resectability and survival in primary retroperitoneal tumors.
- Treatment strategies, including surgery, radiotherapy, and chemotherapy, should be tailored to the specific pathology.
- Further research is needed to improve preoperative diagnosis and long-term outcomes for these rare malignancies.